Xilio Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
828 WINTER STREET, WALTHAM, MA, 02451
Mailing Address
828 WINTER STREET, WALTHAM, MA, 02451
Phone
617-833-1027
Fiscal Year End
1231
EIN
851623397
Financial Overview
FY2025
$154.69M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Secured major partnerships with Gilead Sciences Inc. (2024) and AbbVie Group Holdings (2025), providing crucial funding and external validation.
- Reported positive Phase 1 clinical data for efarindodekin alfa (masked IL-12), showing good tolerability and anti-tumor activity in heavily pre-treated cancer patients.
Material Events
8-K
Financial Distress
March 12, 2026
High Impact
- Maintains Nasdaq listing, crucial for market access and credibility.
- Enhances investor visibility and share liquidity.
8-K
Strategy Change
February 24, 2026
High Impact
- Maintains Nasdaq listing, crucial for accessing capital markets and investor visibility.
- Aims to attract institutional investors by meeting minimum bid price requirements.
Insider Trading
BUY
3 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.